论文部分内容阅读
目的:探讨糖尿病与肾细胞癌发病风险以及临床病理特征的相关性。方法:收集2012年1月~2014年12月183例确诊肾细胞癌患者的临床资料,以同期366例健康体检者作为对照组,比较两组人群在吸烟史、饮酒史、体质指数(BMI)、高血压病史、糖尿病史、恶性肿瘤家族史等资料上的差异;应用非条件Logistic多因素回归分析,评估糖尿病与肾癌发病风险的相关性;将183例肾癌患者根据是否伴有糖尿病分为糖尿病组和非糖尿病组,对比分析两组患者相关临床病理资料的差异。结果:肾癌组和对照组患者中糖尿病的发生率分别为22.7%和14.2%,两组差异有统计学意义(P<0.05);Logistic回归分析结果显示糖尿病史与肾癌发病风险呈正相关(OR=1.415,95%CI:0.876~2.286),但无明显统计学意义(P>0.05);183例肾癌患者中糖尿病组(42例)和非糖尿病组(141例)在年龄分布及肿瘤大小上比较,差异无统计学意义(P>0.05);肾癌合并糖尿病患者中,以男性居多(81.0%),临床分期Ⅲ~Ⅳ期,Fuhrman核分级3~4级所占比例分别为28.6%和42.9%,并发生较多淋巴转移(31.4%)和远处转移(11.9%),与非糖尿病组比较差异有统计学意义(P<0.05)。结论:糖尿病可能会增加罹患肾癌的风险,并影响疾病的预后;糖尿病与肾癌关系密切,在肾癌高危人群和患者中积极预防和控制糖尿病十分重要。
Objective: To investigate the relationship between diabetes mellitus and the risk of renal cell carcinoma and the clinicopathological features. Methods: The clinical data of 183 patients with confirmed renal cell carcinoma from January 2012 to December 2014 were collected. A total of 366 healthy subjects were included as control group. The smoking history, drinking history, body mass index (BMI) , History of hypertension, history of diabetes mellitus, familial history of malignant tumor and so on. Non-conditional logistic regression analysis was used to evaluate the correlation between diabetes and the risk of renal cell carcinoma. 183 patients with renal cell carcinoma were divided according to whether they had diabetes For the diabetic group and non-diabetic group, comparative analysis of the two groups of patients with clinical and pathological data differences. Results: The incidence of diabetes mellitus in patients with renal cell carcinoma and control group were 22.7% and 14.2%, respectively, with significant difference between the two groups (P <0.05). Logistic regression analysis showed that diabetes mellitus had a positive correlation with the incidence of renal cell carcinoma OR = 1.415,95% CI: 0.876-2.286), but there was no statistical significance (P> 0.05). There were no significant differences in age distribution and tumor between 183 cases of renal cell carcinoma (42 cases) and non-diabetic group (81.0%), clinical stage Ⅲ ~ Ⅳ, Fuhrman nuclear grade 3 to 4 were 28.6 % And 42.9% respectively. There were more lymph node metastases (31.4%) and distant metastases (11.9%) than those in non-diabetic patients (P <0.05). Conclusion: Diabetes mellitus may increase the risk of renal cancer and affect the prognosis of the disease. Diabetes mellitus and renal cell carcinoma are closely related. It is very important to prevent and control diabetes mellitus in patients with high risk of renal cell carcinoma and in patients.